REPL
FDA panel day, aka biotech Super Bowl
Replimune got the kind of headline that makes traders spill their coffee: an FDA advisory committee voted that the company’s study of its skin cancer treatment was “clinically meaningful.”
That matters because advisory committee votes aren’t official approvals, but they can be a giant tell. In biotech, this is the difference between “interesting science project” and “hey, there’s a real path here.”
Why investors care
A 132% jump is the market screaming that the odds may have shifted. For a company like Replimune, the whole valuation can hinge on a single drug program, so one supportive panel vote can turn into a full-on rerating.
What to watch next:
- whether the FDA follows the panel’s thinking
- how the company frames the next regulatory steps
- whether this vote translates into a clearer approval path for the treatment
Big picture
Biotech is basically a poker game with lab coats. When the house suddenly seems a little friendlier, the stock can move like it just found a cheat code. That’s what today looked like for Replimune.